49 participants
The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-09-13
- Start Date:
- 2021-09-01
- Completion:
- 2023-06-01
Conditions
- Carrelizumab Plus Lenvatinib Combined With TACE
- Borderline Resectable Hepatocellular Carcinoma
Interventions
- DRUG
No Results Yet